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Multiple sclerosis (MS) is an inﬂammatory disease of the central nervous system (CNS) that involves
myelin, oligodendrocytes and axons and culminates in consecutive neuronal death and progressive neu-
rologic disability. Based on magnetic resonance imaging (MRI), neuroaxonal loss in MS results in brain
atrophy and has a strong correlation with neurological disability.
The newer MR imaging tools seem to be sensitive biomarkers for measuring the pathogenetic processes
associated with disease activity and progression. However, they are unable to detect apoptosis in neuro-
degenerative diseases.
Annexin V has a high afﬁnity for phosphatidylserine (PS) that presents on the outer surface of the
plasma membrane early on during the onset of apoptosis. Radiolabeled annexin V imaging may reveal
the initiation and degree of neuronal apoptosis.
We propose that radiolabeled annexin V imaging is a useful modality in determining apoptosis in MS
and can assess and monitor the effectiveness of neuroprotective and immunomodulatory therapies on
the clinical course of MS.
 2011 Elsevier Ltd. All rights reserved.Introduction
Multiple sclerosis (MS) is an inﬂammatory disease of the central
nervous system (CNS) that involves myelin, oligodendrocytes and
axons and culminates in consecutive neuronal death and progres-
sive neurologic disability [1,2]. Histopathological work-ups have
demonstrated apoptotic neuronal cell death in demyelinated cere-
bral cortex lesions of MS patients [3] that cannot be identiﬁed by
magnetic resonance imaging (MRI). It is difﬁcult to monitor apop-
totic neurons in the human brain in real time because of the rapid
kinetics of apoptosis-related intracellular signaling cascades.
Therefore, much of the current knowledge about apoptotic neuro-
nal cell death in MS comes from studies involving experimental
autoimmune encephalomyelitis (EAE) models [4,5].
Annexin V, a marker of phosphatidylserine (PS) expression, is a
useful means of detecting early apoptosis. In positron emission
tomography (PET) or single photon emission computed tomogra-
phy (SPECT), radiolabeled annexin V can be used to investigate
the apoptosis process in both animal and human models [6]. This
article reviews the pathology of neuronal loss in MS, the role of
apoptosis in this process and its importance in neurological dis-ll rights reserved.
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pums.ac.ir (M. Assadi).ability. We propose that radiolabeled annexin V imaging is a useful
technique in determining apoptosis and monitoring the effect of
neuroprotective and immunomodulatory therapies on the clinical
course of MS.
Atrophy and disability
Neurologic disability in patients with MS has been associated
with atrophy in the brain and spinal cord [7,8]. Brain atrophy is ob-
served when clinical symptoms appear and is noticeable in second-
ary progressive (SP) MS compared to relapsing remitting (RR) MS
[9,10]. Gray matter (GM) atrophy is an important indicator in irre-
versible disability and is observed predominantly in progressive
and chronic forms of MS [11]. On the other hand, early cortical
involvement observed in imaging modalities raises the intriguing
possibility that the GM may represent the primary and initial tar-
gets of the disease process, leading to axonal degeneration and
subsequent demyelination [12].
Cause of atrophy
The amount of tissue loss in MS may represent a balance be-
tween a number of pathological processes: irreversible axonal
and myelin loss on one hand, with partial compensation by inﬂam-
mation-associated cellular inﬁltrates, and cellular (including axo-
nal) and interstitial edema on the other hand [11].
Fig. 1. Maintaining normal membrane polarity by translocase and ﬂoppase activity
and expression of phosphatidylserine due to scramblase activation (Nucl Med
Commun. 2000; 21(3):241–250 with permission).[22].
44 M. Assadi et al. /Medical Hypotheses 77 (2011) 43–46Brain atrophy may derive from antrograde or retrograde neuro-
axonal tract degeneration associated with focal white matter (WM)
inﬂammatory lesions, as well as a process directly targeting neu-
rons and myelin, including cortical demyelination and glia [11].
Axonal loss is a possible contributor to atrophy in MS, although
demyelination and reduced axon diameter may also shrink tissue
volume [13].
Neuroaxonal loss
Axonal damage in MS could result from an immunologic attack,
inﬂammatory mediators or the secondary effects of chronic demy-
elination [14]. It appears that axonal loss begins at the onset of the
disease and remains subclinical during RRMS. The switch from
RRMS to progressive MS could therefore occur when a threshold
of neuronal or axonal loss is achieved or when adaptive responses
of the CNS are exhausted [15]. Peterson et al. identiﬁed transected
axons, transected dendrites and neuronal cell death in cortical MS
lesions in patients aged two weeks to 27 years with clinical disease
[3]. In addition, Lovas et al. described about a 57% reduction in ax-
onal density of normal-appearing white matter (NAWM) from cer-
vical spinal cords in SPMS patients [16].
Diminished N-acetylaspartate [17] and progressive CNS atrophy
[8] seen on MRIs are noninvasive indicators of axonal loss in MS
patients. Axonal damage is probably caused by proteolytic en-
zymes, cytokines and free radicals mainly generated by activated
immune and glial cells in an inﬂammatory response [18]. It has
been suggested that in the course of EAE, a lymphocyte attack
may play a role in both oligodendrocyte and neuron degeneration,
as happens with motoneurons in the spinal cord [19]. Alterna-
tively, an inﬂammatory axonal transection in WM and the cortex
might initiate a retrograde degeneration of neurons and apoptosis
and a Wallerian degeneration distal to the site of the transaction
[15].
Apoptosis and evidence
Apoptosis is an important feature of nervous system develop-
ment and appears to play a role in several neurodegenerative dis-
eases, such as amyotrophic lateral sclerosis, Parkinson’s disease
and Alzheimer’s disease [20]. Neuronal apoptosis occurs in the
EAE model and in MS plaques that involve both spinal cord and
cerebral cortical GM [3,21]. Peterson et al. combined a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) as-
say and neuroﬁlament immunocytochemistry (ICC) to investigate
neuronal apoptosis in 22 MS lesions from seven patients. They
found apoptotic neurons in 56% of the chronic active lesions and
in 45% of the chronic inactive lesions, but not in the active lesions.
Most of the apoptotic neurons were large and pyramidal and were
located in cortical layers 3 and 5. Since apoptotic neurons are
cleared within 24 h, neuronal loss by apoptosis could be very sig-
niﬁcant and cumulate over time [3].
Apoptosis source
Cerebrospinal ﬂuid (CSF) from MS patients provokes apoptotic
neuronal death in cell cultures, indicating that apoptosis results
from immunomodulatory and inﬂammatory mediators during
demyelination [22,23]. Axonotmesis as a result of inﬂammation
in MS lesions can also lead to retrograde neuronal degeneration
and apoptosis [15].
After demyelination in the WM, alterations in the distribution
of sodium channels occur along the demyelinated axons that are
positive for amyloid precursor protein (a marker for axonal dam-
age). Although this redistribution of ion channels improves the
functionality of injured axons, it demands higher cellular adeno-sine triphosphate (ATP); therefore, it increases the energy expendi-
ture of neuronal conduction, with concurrent abnormalities found
in mitochondrial functioning. Higher energy demands and ham-
pered mitochondrial functions make demyelinated axons more
susceptible to hypoxic damage, which ultimately results in neuro-
axonal degeneration [2].Apoptosis detection
Apoptosis is preceded by the selective exposure of PS on cell
surfaces. All cells, including neurons, rapidly redistribute PS, an an-
ionic constitutive membrane lipid, from the inner to outer leaﬂets
of the plasma membrane shortly after the onset of apoptosis [22].
In contrast to the other lipids, PS is restricted to the inner leaﬂet of
the cell membrane as a result of the action of translocase and ﬂop-
pase enzymes. When the caspase cascade is activated in an apop-
totic cell, the above-mentioned enzymes are inactivated (Fig. 1)
[22,24,25].
Annexin V is normally found in the cytoplasm of a variety of
cells that have a high afﬁnity for cell surface-exposed PS [26]. Fluo-
rescent or biotin-labeled annexin V are the most widely used non-
nuclear modalities in in vitro detection of apoptosis. An alternative
approach uses radiolabeled forms of annexin V for PET or SPECT to
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Tc-99m-annexin is accumulated mainly in the kidneys, liver and
spleen [27]. Since uptake in the normal brain is negligible, it is
an ideal tracer for apoptosis detection in the brain [28]. Recent
investigations have shown that neurons in regions of augmented
annexin V uptake with low to moderate levels of PS expression
were under stress and experienced reversible apoptosis, whereas
regions with high levels of PS expression have irreversible apopto-
sis and dying neurons [29].
In comparison of PET using ﬂuorine-18 and 124 I labeling of an-
nexin V with SPECT using 99mTc-annexin V, the uptake of PET
radiotracers in the liver, spleen and kidney is lower than 99mTc-
annexin V [30,31]. Therefore, radiolabeled annexin V with PET
radiotracers facilitates better apoptosis imaging in the abdominal
region relative to most forms of 99mTc-annexin V [30,31]. In addi-
tion, because of higher contrast and spatial resolution of PET sys-
tem rather than SPECT imaging, radiolabeled annexin V with PET
radiotracers results to better detection and quantitation of the
apoptotic lesions [22].
Blankenberg et al. investigated if technetium-99m (99mTc)
conjugated with annexin V could identify hypoxic/ischemic cere-
bral reperfusion injury (HII) in animal model imaging. As early as
2 h following reperfusion, radiolabelled annexin V images revealed
a two to threefold increase in annexin V uptake in the involved
hemisphere compared with the normal contralateral hemisphere.
There was no evidence of blood brain barrier (BBB) breakdown fol-
lowing reperfusion, as demonstrated by contemporaneous 99Tcm-
DTPA imaging [22]. D’Arceuil et al. also showed that 99mTc-HY-
NIC-annexin V imaging could identify neuronal apoptosis within
2 h after the reversal of hypoxia in an animal model of global cere-
bral ischemia [32]. Lampl et al. also evaluated the feasibility of PS
imaging in the brains of patients with Alzheimer’s disease using
99mTc-HYNIC-annexin V SPECT [33].
In dosimetric assessment, use of 99mTc-annexin V to patients
develops an effective dose of 7.6 ± 0.5 microsievert/megabecquerel
(lSv/MBq), congruent with a total effective dose of 4.6 ± 0.3 milli-
sievert (mSv) for a typical patient dose of 600 MBq [27] which are
in the lower range of values reported for commonly used 99mTc
compounds [34]. It reﬂects that it is a safe radiopharmaceutical
with an acceptable radiation dose [35]. Therefore, this point is an
important value when serial monitoring of apoptosis in the same
patient is needed.
Hypothesis. Radiolabeled annexin V imaging can be a determinate
of apoptosis in MS.
Radiolabeled-annexin V imaging may also determine apoptosis
in MS patients. As discussed above, MS pathology involves inﬂam-
matory demyelination and neurodegeneration. The latter, arising
from apoptosis, is considered the main cause of disability in MS pa-
tients. These newer tools seem to be sensitive biomarkers for mea-
suring the pathogenetic processes associated with disease activity
and progression, but they are not capable of identifying pro-
grammed neuronal death. However, radiolabeled annexin V imag-
ing may be a determinate of the beginning and degree of neuronal
apoptosis.
Potential implications
Although immunomodulatory therapies such as beta-interferon
have shown efﬁcacy in reducing new WM lesion formations in MS
patients, the degenerative phase of the disease may not be fully
interrupted and their effect in reducing atrophy, as a marker of
neurodegeneration, has been modest [10,11]. Research now fo-
cuses on a new class of treatments, such as Epo [36] or ciliary neu-
rotrophic factor [37] and even glatiramer acetate [38], that targetneuroprotection rather than a reduction of inﬂammation. Brain
atrophy is frequently used as an outcomemeasure in treatment tri-
als and is estimated using conventional MRI metrics [39]. However,
this technique is unable to directly identify the apoptosis process
in this neurodegenerative disorder. Radiolabeled-annexin V seems
to be helpful in identifying disease activity and the efﬁcacy of the
neuroprotective agents.Conﬂict of interest statement
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